Structures by: Reddy L. S.
Total: 90
1:1 complex of barbituric acid and quinoxaline-N,N'-oxide
C8H6N2O2,C4H4N2O3
Molecular Pharmaceutics (2007) 4, 3 417
a=10.3850(9)Å b=7.2222(6)Å c=16.3763(14)Å
α=90.00° β=93.6860(10)° γ=90.00°
1:2 Cocrystal of Barbituric acid and 4-methylpyridine N-oxide
2(C6H7NO),C4H4N2O3
Molecular Pharmaceutics (2007) 4, 3 417
a=8.4083(7)Å b=9.8893(9)Å c=10.6761(9)Å
α=73.2010(10)° β=79.022(2)° γ=74.182(2)°
2:1 Cocrystal of Barbituric acid and 4,4'pyrazine-N,N'-dioxide
C4H4N2O3,0.5(C4H4N2O2)
Molecular Pharmaceutics (2007) 4, 3 417
a=5.258(3)Å b=6.478(3)Å c=22.118(11)Å
α=90.00° β=95.795(8)° γ=90.00°
1:1 complex of saccharin and bipyridine-N,N'-oxide
C10H8N2O2,2(C7H5NO3S)
Molecular Pharmaceutics (2007) 4, 3 417
a=6.5207(4)Å b=14.0377(9)Å c=13.1232(9)Å
α=90.00° β=104.2800(10)° γ=90.00°
2:1 cocrystal of 4-methylpyridine-N-oxide and barbital
C8H12N2O3,C5H5NO
Molecular Pharmaceutics (2007) 4, 3 417
a=7.2276(5)Å b=19.5811(12)Å c=9.9928(6)Å
α=90.00° β=98.1360(10)° γ=90.00°
1:1 cocrystal of 4-hydroxybenzamide and bipyridine-N,N'-dioxide
C10H8N2O2,2(C7H7NO2)
Molecular Pharmaceutics (2007) 4, 3 417
a=5.692(4)Å b=9.482(6)Å c=10.751(7)Å
α=69.893(10)° β=84.232(10)° γ=84.969(10)°
Hydrate of 1:1 cocrystal of 4-hydroxy benzamide and pyrazine-4,4'-dioxide
C7H7NO2,0.5(C4H4N2O2),H2O
Molecular Pharmaceutics (2007) 4, 3 417
a=6.409(4)Å b=7.372(4)Å c=11.064(6)Å
α=96.127(14)° β=97.22(3)° γ=105.350(9)°
2:4 Cocrystal of Barbital acid and 4-methylpyridine N-oxide
C8H12N2O3,2(C6H7NO)
Molecular Pharmaceutics (2007) 4, 3 417
a=8.2106(5)Å b=23.9166(15)Å c=20.6318(13)Å
α=90.00° β=96.6700(10)° γ=90.00°
1:0.5 cocrystal of Carbamazepine and Quinoxaline-N,N'-dioxide
C15H12N2O,C8H6N2O2
Molecular Pharmaceutics (2007) 4, 3 417
a=7.284(2)Å b=10.688(4)Å c=14.132(5)Å
α=100.250(5)° β=102.463(5)° γ=109.079(5)°
1:0.5 cocrystal of Carbamazepine and pyrazine-N,N'-dioxide
C15H12N2O,0.5(C4H4N2O2)
Molecular Pharmaceutics (2007) 4, 3 417
a=10.237(4)Å b=27.247(12)Å c=5.135(2)Å
α=90.00° β=102.708(7)° γ=90.00°
C21H18F3NO4
C21H18F3NO4
Green Chemistry (2012) 14, 7 1870
a=13.6247(14)Å b=8.6852(8)Å c=17.0833(19)Å
α=90.00° β=112.949(2)° γ=90.00°
C11H10N4O,(H2O)
C11H10N4O,(H2O)
CrystEngComm (2008) 10, 12 1735
a=7.0172(14)Å b=10.343(2)Å c=15.516(3)Å
α=90.00° β=90.00° γ=90.00°
Cis,cis-1,3,5-cyclohexanetricarboxylic acid - (4(3H)- pyrimidone)2
(C9H12O6),2(C4H4N2O)
CrystEngComm (2008) 10, 12 1735
a=13.3218(14)Å b=5.7554(6)Å c=24.093(3)Å
α=90.00° β=90.508(2)° γ=90.00°
DMSO solvate of N-(4-iodophenyl)-N'-(4'-nitrophenyl)-urea
C13H10IN3O3,C2H6SO
Crystal Growth & Design (2007) 7, 12 2675-2690
a=10.184(2)Å b=13.346(3)Å c=15.502(3)Å
α=66.82(3)° β=88.22(3)° γ=68.75(3)°
C13H10FN3O3
C13H10FN3O3
Crystal Growth & Design (2007) 7, 12 2675-2690
a=8.1241(8)Å b=12.9932(12)Å c=11.6524(11)Å
α=90.00° β=94.967(2)° γ=90.00°
C14H10N4O3
C14H10N4O3
Crystal Growth & Design (2007) 7, 12 2675-2690
a=7.919(4)Å b=13.692(6)Å c=11.777(6)Å
α=90.00° β=94.517(10)° γ=90.00°
N-(3-bromophenyl)-N'-(4-nitrophenyl)urea
C13H10BrN3O3
Crystal Growth & Design (2007) 7, 12 2675-2690
a=8.4078(9)Å b=12.7289(13)Å c=12.3376(13)Å
α=90.00° β=97.552(2)° γ=90.00°
C13H10IN3O3
C13H10IN3O3
Crystal Growth & Design (2007) 7, 12 2675-2690
a=8.4419(17)Å b=12.987(3)Å c=12.399(3)Å
α=90.00° β=96.59(3)° γ=90.00°
C13H11N3O3,C3H7NO
C13H11N3O3,C3H7NO
Crystal Growth & Design (2007) 7, 12 2675-2690
a=9.4442(19)Å b=7.3883(15)Å c=23.863(5)Å
α=90.00° β=97.73(3)° γ=90.00°
C14H13N3O3
C14H13N3O3
Crystal Growth & Design (2007) 7, 12 2675-2690
a=6.8807(5)Å b=12.7415(10)Å c=15.2876(11)Å
α=84.9720(10)° β=81.1590(10)° γ=80.6540(10)°
DMF solvate of N-(4-cyanophenyl)-N'-(4-nitrophenyl)urea
C14H10N4O3,C3H7NO
Crystal Growth & Design (2007) 7, 12 2675-2690
a=7.9488(7)Å b=10.4797(9)Å c=11.9563(10)Å
α=114.6710(10)° β=95.441(2)° γ=101.2000(10)°
DMSO solvate of N-(4-iodophenyl)-N'-(4'-nitrophenyl)-urea
C13H10IN3O3,C2H6SO
Crystal Growth & Design (2007) 7, 12 2675-2690
a=10.184(2)Å b=13.346(3)Å c=15.502(3)Å
α=66.82(3)° β=88.22(3)° γ=68.75(3)°
DMSO solvate of N-(4-nitropheny)-N'-(4-carboxamidophenyl)-urea
C14H12N4O4,C2H6SO
Crystal Growth & Design (2007) 7, 12 2675-2690
a=8.4835(13)Å b=9.5690(14)Å c=11.8457(18)Å
α=105.069(3)° β=103.506(3)° γ=98.203(3)°
C14H13N3O3,C2H6OS
C14H13N3O3,C2H6OS
Crystal Growth & Design (2007) 7, 12 2675-2690
a=16.0665(10)Å b=5.7448(4)Å c=39.100(3)Å
α=90.00° β=100.115(2)° γ=90.00°
C15H13N3O4,C2H6OS
C15H13N3O4,C2H6OS
Crystal Growth & Design (2007) 7, 12 2675-2690
a=6.0509(6)Å b=12.4575(12)Å c=12.5937(11)Å
α=78.120(2)° β=82.891(2)° γ=80.105(2)°
C13H9F2N3O3,C2H6OS
C13H9F2N3O3,C2H6OS
Crystal Growth & Design (2007) 7, 12 2675-2690
a=9.1958(10)Å b=9.5491(10)Å c=10.5716(11)Å
α=69.9990(10)° β=79.3480(10)° γ=69.5910(10)°
Hydrate of N-(4-nitropheny)-N'-(3-hydroxyphenyl)-urea
C13H11N3O4,H2O
Crystal Growth & Design (2007) 7, 12 2675-2690
a=6.7307(10)Å b=10.2019(15)Å c=10.2840(15)Å
α=77.995(3)° β=84.110(3)° γ=75.686(3)°
C15H16N4O3
C15H16N4O3
Crystal Growth & Design (2007) 7, 12 2675-2690
a=6.0710(12)Å b=7.5613(15)Å c=31.715(6)Å
α=89.95(3)° β=87.01(3)° γ=85.23(3)°
N-(4'-iodobiphenyl)-4'-(nitrophenyl)-urea
C19H14IN3O3
Crystal Growth & Design (2007) 7, 12 2675-2690
a=14.3837(15)Å b=9.3167(10)Å c=13.3889(14)Å
α=90.00° β=104.847(2)° γ=90.00°
C14H13N3O3
C14H13N3O3
Crystal Growth & Design (2007) 7, 12 2675-2690
a=9.851(3)Å b=56.994(18)Å c=9.211(3)Å
α=90.00° β=90.00° γ=90.00°
1,3-bis(3-pyridyl)ureahydrate(3:4)
C11H10N40,4/3(H2O)
Crystal Growth & Design (2006) 6, 1 161
a=12.941(3)Å b=11.789(2)Å c=22.401(5)Å
α=90.00° β=101.37(3)° γ=90.00°
N,N'-bis(3-pyridyl)urea+succinicacid
C11H11N4O,C4H5O4
Crystal Growth & Design (2006) 6, 1 161
a=38.093(8)Å b=5.2820(11)Å c=16.428(3)Å
α=90.00° β=109.35(3)° γ=90.00°
N-(3-pyridyl)-N'-phenylurea
C12H11N3O
Crystal Growth & Design (2006) 6, 1 161
a=11.7789(13)Å b=9.4606(10)Å c=18.262(2)Å
α=90.00° β=90.00° γ=90.00°
N,N'-bis(3-pyridyl)urea+Fumaricacid+water
C11H11N4O,C4H3O4,H2O
Crystal Growth & Design (2006) 6, 1 161
a=7.404(2)Å b=8.068(4)Å c=13.562(3)Å
α=104.55(3)° β=98.02(2)° γ=95.52(3)°
1,3-bis(3-N-methylpyridinium)urea diiodide
C13H16N4O,2(I)
Crystal Growth & Design (2006) 6, 1 161
a=7.7439(15)Å b=10.464(2)Å c=10.683(2)Å
α=101.42(3)° β=100.55(3)° γ=99.28(3)°
1,3-bis(3-pyridyl)urea
C11H10N4O
Crystal Growth & Design (2006) 6, 1 161
a=13.707(3)Å b=7.0140(14)Å c=10.006(2)Å
α=90.00° β=90.00° γ=90.00°
1,3-bis(3-pyridyl)ureadihydrate
C11H10N4O,2(H2O)
Crystal Growth & Design (2006) 6, 1 161
a=6.7932(8)Å b=19.560(2)Å c=9.2746(11)Å
α=90.00° β=101.260(2)° γ=90.00°
1,3-bis(3-pyridyl)urea dihydrate
C11H10N4O,2(H2O)
Crystal Growth & Design (2006) 6, 1 161
a=6.8138(5)Å b=19.586(11)Å c=9.292(4)Å
α=90.00° β=101.24(3)° γ=90.00°
N,N'-bis(3-pyridyl-N-oxide)urea dihydrate
C11H10N4O3,H2O
Crystal Growth & Design (2006) 6, 1 161
a=7.9686(7)Å b=12.2243(11)Å c=24.538(2)Å
α=90.00° β=90.650(2)° γ=90.00°
1:2 complex of pluoroglucinol and acridine
2(C13H9N),(C6H6O3)
Crystal Growth & Design (2008) 8, 12 4546
a=12.3666(14)Å b=13.7140(16)Å c=14.0060(15)Å
α=90.00° β=90.00° γ=90.00°
1:2:1 complex of pluoroglucinol, phenazine and water
2(C12H8N2),(C6H6O3),H2O
Crystal Growth & Design (2008) 8, 12 4546
a=7.3484(9)Å b=9.2233(11)Å c=18.743(2)Å
α=94.272(2)° β=100.101(2)° γ=94.900(2)°
1:1.5 Complex of pluoroglucinol and phenazine
1.5(C12H8N2),(C6H6O3)
Crystal Growth & Design (2008) 8, 12 4546
a=9.8825(12)Å b=12.5062(15)Å c=16.2270(19)Å
α=90.00° β=100.447(2)° γ=90.00°
2:3.5 molecular complex of phluoroglucinol and phenazine
3.5(C12H8N2),2(C6H6O3)
Crystal Growth & Design (2008) 8, 12 4546
a=9.4776(10)Å b=14.1266(15)Å c=17.4609(18)Å
α=70.605(2)° β=82.982(2)° γ=73.717(2)°
0.5:1 complex of pluoroglucinol and phenazine
(C12H8N2),0.5(C6H6O3)
Crystal Growth & Design (2008) 8, 12 4546
a=14.159(3)Å b=11.943(3)Å c=14.249(3)Å
α=90.00° β=102.423(5)° γ=90.00°
2,4,6-tris(4-iodophenoxy)-1,3,5-triazine, dichloromethane
2(C21H12N3O3I3),CH2Cl2
Crystal Growth & Design (2005) 5, 3 887
a=15.7177(5)Å b=15.7177(5)Å c=18.9157(9)Å
α=90.00° β=90.00° γ=120.00°
2,4,6-tris(4-bromophenoxy)-1,3,5-triazine, hexafluorobenzene
2(C21H12Br3N3O3),C6F6
Crystal Growth & Design (2005) 5, 3 887
a=15.1070(9)Å b=15.1070(9)Å c=18.019(2)Å
α=90.00° β=90.00° γ=120.00°
2,4,6-tris(4-iodophenoxy)-1,3,5-triazine, hexachlorobenzene
2(C21H12I3N3O3),C6Cl6
Crystal Growth & Design (2005) 5, 3 887
a=15.686(4)Å b=15.686(4)Å c=18.583(7)Å
α=90.00° β=90.00° γ=120.00°
2,4,6-tris(4-iodophenoxy)-1,3,5-triazine, collidine
2(C21H12I3N3O3),C8H11N
Crystal Growth & Design (2005) 5, 3 887
a=15.619(2)Å b=15.619(2)Å c=18.361(4)Å
α=90.00° β=90.00° γ=120.00°
2,4,6-tris(4-iodophenoxy)-1,3,5-triazine, mesitylene
2(C21H12I3N3O3),C9H12
Crystal Growth & Design (2005) 5, 3 887
a=15.668(3)Å b=15.668(3)Å c=18.475(5)Å
α=90.00° β=90.00° γ=120.00°
2,4,6-tris(4-iodophenoxy)-1,3,5-triazine, dibromomethane
C45H30Br3I6N6O6
Crystal Growth & Design (2005) 5, 3 887
a=15.6595(13)Å b=15.6595(13)Å c=18.681(2)Å
α=90.00° β=90.00° γ=120.00°
2,4,6-tris(4-iodophenoxy)-1,3,5-triazine, tribromomesitylene
2(C21H12I3N3O3),C9H9Br3
Crystal Growth & Design (2005) 5, 3 887
a=15.7356(8)Å b=15.7356(8)Å c=18.3863(13)Å
α=90.00° β=90.00° γ=120.00°
2,4,6-tris(4-iodophenoxy)-1,3,5-triazine, hexafluorobenzene
2(C21H12I3N3O3),C6F6
Crystal Growth & Design (2005) 5, 3 887
a=15.5466(4)Å b=15.5466(4)Å c=18.1511(11)Å
α=90.00° β=90.00° γ=120.00°
2,4,6-tris(4-iodophenoxy)-1,3,5-triazine, 1,3,5-triiodomesitylene
2(C21H12I3N3O3),C9H9I3
Crystal Growth & Design (2005) 5, 3 887
a=15.9236(9)Å b=15.9236(9)Å c=18.425(2)Å
α=90.00° β=90.00° γ=120.00°
2,4,6-tris(4-iodophenoxy)-1,3,5-triazine, 1-methylnapthalene
2(C21H12N3O3I3),C11H10
Crystal Growth & Design (2005) 5, 3 887
a=15.5830(6)Å b=15.5830(6)Å c=18.3563(14)Å
α=90.00° β=90.00° γ=120.00°
1:1 molecular complex of benzamide and pentafluorobenzamide
C7H2F5NO,C7H7NO
Crystal Growth & Design (2004) 4, 1 89
a=7.3546(3)Å b=6.0207(2)Å c=14.7507(5)Å
α=90.00° β=90.568(2)° γ=90.00°
1:1 molecular complex of benzamide and pentafluorobenzoic acid
(C7H7NO).(C7HF5O2)
Crystal Growth & Design (2004) 4, 1 89
a=11.290(2)Å b=6.7326(13)Å c=18.085(4)Å
α=90.00° β=105.04(3)° γ=90.00°
Pentafluorobenzamide
C7H2F5NO
Crystal Growth & Design (2004) 4, 1 89
a=12.749(3)Å b=6.1977(12)Å c=9.5974(19)Å
α=90.00° β=99.94(3)° γ=90.00°
1:1 molecular complex of benzoic acid and pentafluorobenzoic acid
C7HF5O2,C7H6O2
Crystal Growth & Design (2004) 4, 1 89
a=24.7320(4)Å b=7.74200(10)Å c=14.3430(3)Å
α=90.00° β=108.4210(10)° γ=90.00°
6-amino-2-(2-chlorophenylsulfonylimino)-1,2-dihydropyridine
C11H10ClN3O2S
Crystal Growth & Design (2004) 4, 4 701
a=9.232(6)Å b=8.900(6)Å c=15.102(9)Å
α=90.00° β=96.081(11)° γ=90.00°
6-amino-2-(2-methylphenylsulfonylimino)-1,2-dihydropyridine
C12H13N3O2S
Crystal Growth & Design (2004) 4, 4 701
a=9.169(2)Å b=8.867(2)Å c=15.222(4)Å
α=90.00° β=96.511(5)° γ=90.00°
6-amino-2-(3-methylphenylsulfonylimino)-1,2-dihydropyridine
C12H13N3O2S
Crystal Growth & Design (2004) 4, 4 701
a=12.434(4)Å b=10.396(4)Å c=9.113(3)Å
α=90.00° β=92.247(6)° γ=90.00°
6-amino-2-(4-fluorophenylsulfonylimino)-1,2-dihydropyridine
C11H10FN3O2S
Crystal Growth & Design (2004) 4, 4 701
a=9.000(6)Å b=8.618(6)Å c=14.643(10)Å
α=90.00° β=91.698(17)° γ=90.00°
6-amino-2-(4-chlorophenylsulfonylimino)-1,2-dihydropyridine
C11H10ClN3O2S
Crystal Growth & Design (2004) 4, 4 701
a=13.725(6)Å b=7.312(3)Å c=25.419(11)Å
α=90.00° β=92.886(8)° γ=90.00°
6-amino-2-(4-bromophenylsulfonylimino)-1,2-dihydropyridine
C11H10BrN3O2S
Crystal Growth & Design (2004) 4, 4 701
a=10.7951(9)Å b=18.2559(15)Å c=26.335(2)Å
α=90.00° β=94.330(2)° γ=90.00°
6-amino-2-(4-iodophenylsulfonylimino)-1,2-dihydropyridine
C11H10IN3O2S
Crystal Growth & Design (2004) 4, 4 701
a=10.755(2)Å b=18.300(3)Å c=26.828(5)Å
α=90.00° β=90.00° γ=90.00°
6-amino-2-(4-methylphenylsulfonylimino)-1,2-dihydropyridine
C12H13N3O2S
Crystal Growth & Design (2004) 4, 4 701
a=15.015(6)Å b=10.880(5)Å c=17.066(7)Å
α=90.00° β=113.457(8)° γ=90.00°
6-amino-2-(4-methoxyphenylsulfonylimino)-1,2-dihydropyridine
C12H13N3O3S
Crystal Growth & Design (2004) 4, 4 701
a=10.614(3)Å b=18.276(5)Å c=27.402(7)Å
α=90.00° β=90.00° γ=90.00°
6-amino-2-(4-methylphenylsulfonylimino)-1,2-dihydropyridine
C12H13N3O2S
Crystal Growth & Design (2004) 4, 4 701
a=10.834(3)Å b=17.749(4)Å c=26.473(7)Å
α=90.00° β=94.531(7)° γ=90.00°
6-amino-2-[4-(trifluoromethyl)phenylsulfonylimino]-1,2-dihydropyridine
C12H10F3N3O2S
Crystal Growth & Design (2004) 4, 4 701
a=10.8897(13)Å b=18.343(2)Å c=26.640(3)Å
α=90.00° β=90.00° γ=90.00°
Carbamazepine:benzoic acid cocrystal (1:1)
C22H18N2O3
Crystal Growth & Design (2009) 9, 4 1869
a=28.5185(18)Å b=5.1607(4)Å c=24.7363(15)Å
α=90.00° β=103.448(4)° γ=90.00°
Carbamazepine:4-hydroxybenzoic acid cocrystal, form C (1:1)
C15H12N2O,C7H6O3
Crystal Growth & Design (2009) 9, 4 1869
a=13.3059(9)Å b=6.6658(4)Å c=20.7091(14)Å
α=90.00° β=91.0140(10)° γ=90.00°
Carbamazepine host structure with 4-hydroxybenzoic acid removed
C15H12N2O
Crystal Growth & Design (2009) 9, 4 1869
a=20.4438(9)Å b=5.1527(2)Å c=26.5197(12)Å
α=90.00° β=95.264(2)° γ=90.00°
Carbamazepine:glutaric acid cocrystal (1:1)
C20H20N2O5
Crystal Growth & Design (2009) 9, 4 1869
a=18.5619(10)Å b=5.1201(3)Å c=19.4588(9)Å
α=90.00° β=106.839(3)° γ=90.00°
Carbamazepine host structure with malonic acid removed
C15H12N2O
Crystal Growth & Design (2009) 9, 4 1869
a=10.3327(15)Å b=26.611(5)Å c=5.0875(9)Å
α=90.00° β=104.258(9)° γ=90.00°
Carbamazepine:salicylic acid cocrystal (1:1)
C22H18N2O4
Crystal Growth & Design (2009) 9, 4 1869
a=5.1064(6)Å b=19.783(2)Å c=18.328(2)Å
α=90.00° β=97.903(7)° γ=90.00°
Carbamazepine host structure with DL-tartaric acid removed
C15H12N2O
Crystal Growth & Design (2009) 9, 4 1869
a=10.3006(9)Å b=26.972(2)Å c=5.0718(4)Å
α=90.00° β=104.235(6)° γ=90.00°
Carbamazepine:1-hydroxy-2-naphthoic acid cocrystal (1:1)
C26H20N2O4
Crystal Growth & Design (2009) 9, 4 1869
a=16.6411(13)Å b=5.0526(5)Å c=24.493(2)Å
α=90.00° β=99.062(6)° γ=90.00°
Carbamazepine host structure with maleic acid removed
C15H12N2O
Crystal Growth & Design (2009) 9, 4 1869
a=10.4207(14)Å b=26.168(4)Å c=5.2089(7)Å
α=90.00° β=104.346(9)° γ=90.00°
Carbamazepine host structure with oxalic acid removed
C15H12N2O
Crystal Growth & Design (2009) 9, 4 1869
a=10.330(14)Å b=26.24(3)Å c=5.110(6)Å
α=90.00° β=104.21(3)° γ=90.00°
Carbamazepine:(+)-camphoric acid cocrystal (1:1)
C25H28N2O5
Crystal Growth & Design (2009) 9, 4 1869
a=12.5885(6)Å b=13.1453(6)Å c=14.4820(7)Å
α=90.00° β=105.745(2)° γ=90.00°
C9H17NO2,C7H6O3
C9H17NO2,C7H6O3
Crystal Growth & Design (2009) 9, 1 378
a=12.8276(12)Å b=25.380(2)Å c=9.5029(9)Å
α=90.00° β=90.00° γ=90.00°
C16H23NO5
C16H23NO5
Crystal Growth & Design (2009) 9, 1 378
a=6.0648(4)Å b=11.0825(8)Å c=12.5727(9)Å
α=66.3550(10)° β=83.4020(10)° γ=85.7140(10)°
C9H18NO2,C7H5O3
C9H18NO2,C7H5O3
Crystal Growth & Design (2009) 9, 1 378
a=10.5813(9)Å b=10.3920(9)Å c=28.659(3)Å
α=90.00° β=96.573(1)° γ=90.00°
C9H18NO2,C11H7O3
C9H18NO2,C11H7O3
Crystal Growth & Design (2009) 9, 1 378
a=7.3565(6)Å b=18.4929(15)Å c=13.7524(11)Å
α=90.00° β=101.8550(10)° γ=90.00°
C9H18NO2,C8H7O3
C9H18NO2,C8H7O3
Crystal Growth & Design (2009) 9, 1 378
a=6.1129(10)Å b=9.3483(15)Å c=14.879(2)Å
α=76.397(3)° β=84.535(3)° γ=79.731(3)°
C15H12N2O,C7H7NO2
C15H12N2O,C7H7NO2
Crystal Growth & Design (2009) 9, 2 889
a=5.1909(4)Å b=18.4126(13)Å c=19.0481(14)Å
α=90.00° β=97.7740(10)° γ=90.00°
N-(4-carboxamidophenyl)-N'-(nitrophenyl)urea.DMF
C14H12N4O4,C3H7NO
Crystal Growth & Design (2007) 7, 12 2675-2690
a=7.4728(10)Å b=10.2624(14)Å c=12.5410(17)Å
α=105.841(2)° β=104.695(3)° γ=95.110(3)°
2,4,6-tris(4-iodophenoxy)-1,3,5-triazine, diiodomethane
C22H14I5N3O3
Crystal Growth & Design (2005) 5, 3 887
a=15.6962(10)Å b=15.6962(10)Å c=18.9478(18)Å
α=90.00° β=90.00° γ=120.00°
6-amino-2-(4-nitrophenylsulfonylimino)-1,2-dihydropyridine
C11H12N4O5S
Crystal Growth & Design (2004) 4, 4 701
a=14.663(16)Å b=12.276(16)Å c=7.589(11)Å
α=90.00° β=96.16(9)° γ=90.00°
Carbamazepine:4-hydroxybenzoic acid cocrystal, form A (1:1)
C22H18N2O4
Crystal Growth & Design (2009) 9, 4 1869
a=7.0994(3)Å b=12.7087(6)Å c=20.1105(9)Å
α=90.00° β=91.870(2)° γ=90.00°